Literature review · Sexual & reproductive health

PT-141 (bremelanotide)

Bremelanotide has controlled clinical evidence in a defined sexual-desire disorder and earlier intranasal pharmacology research. The study products are not interchangeable with catalogue materials.

By HeartPep · Reviewed · 3 selected source records

Buy from HeartPep.com

Laboratory research only. Not for human or veterinary use.

At a glance

The selected papers span early route-specific experiments, placebo-controlled phase 3 trials and an optional 52-week open-label extension with substantial attrition.

Identity & scope

PT-141 is also known as bremelanotide, a melanocortin analogue. Identifying the compound does not establish a supplier product’s composition, delivery characteristics or batch quality.

Catalogue labels covered: PT-141.

What the research shows

  • A positive questionnaire endpoint in a defined disorder cannot be generalized to everyone or every sexual-function outcome.
  • An intranasal research paper is relevant background for that route, but does not validate another spray formulation.

Critical interpretation

The endpoint hierarchy limits the headline

RECONNECT met its desire and distress coprimary endpoints. The key secondary count of satisfying sexual events did not significantly differ, after which later ranked endpoints were supportive or exploratory. This does not erase the primary findings; it identifies what improved and what did not. Differential withdrawals and the handling of missing observations further matter when interpreting the size and persistence of the effect. A review should retain this endpoint structure rather than flatten every sexual-function measure into one positive result. [1]

Longer follow-up is useful, but the cohort is selected

The 52-week extension describes people who completed the core trial, remained eligible and chose to continue; only 272 of 684 entrants completed the extension. Without continued blinding and a placebo comparator, changes in that group cannot provide the same causal estimate as the original randomised phase. The earlier nasal paper is also route-specific experimental evidence, not proof of equivalence between any commercial nasal preparation and the later injected medicine. These sources answer different questions about time, population and delivery. [3] [2]

Limitations & uncertainties

  • Adverse effects and tolerability are part of the results, not evidence that catalogue products are suitable for personal use.
  • No cited trial tested the supplied research products or their exact containers and formulations.

Open research questions

  • Is the paper studying desire, distress, erectile response or another endpoint?
  • Does the experimental material match the molecule, formulation and analytical specification in the source?

Selected papers & source records

Download bibliography
Human studyNamed compoundFull text consulted

1. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials (opens in a new tab)

Kingsberg SA, Clayton AH, Portman D, et al. (2019). Obstetrics & Gynecology. DOI: 10.1097/AOG.0000000000003500 (opens in a new tab) · PMID 31599840

Design & population
Two 24-week randomized double-blind placebo-controlled RECONNECT trials;1,267 premenopausal women with hypoactive sexual desire disorder were randomized.
What the study found
The clinical formulation improved desire and related-distress scores versus placebo. The key secondary count of satisfying sexual events did not differ significantly; nausea, flushing and headache were more common.
Limits on interpretation
Differential withdrawal rates and last-observation-carried-forward analyses complicate interpretation. Selected full-text methods, endpoint hierarchy and limitations sections were consulted.
Human studyNamed compoundAbstract / record checked

2. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction (opens in a new tab)

Diamond LE, Earle DC, Rosen RC, Willett MS, Molinoff PB. (2004). International Journal of Impotence Research. DOI: 10.1038/sj.ijir.3901139 (opens in a new tab) · PMID 14963471

Design & population
Early double-blind placebo-controlled intranasal studies in healthy men and sildenafil-responsive men with erectile dysfunction; objective erectile responses were measured.
What the study found
An erectile response was observed with the study formulation. Flushing and nausea were the common reported adverse effects.
Limits on interpretation
Early pharmacology experiments in selected men. A matching route name does not make a current catalogue spray equivalent in composition, delivery or quality.
Human studyNamed compoundAbstract / record checked

3. Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder (opens in a new tab)

Simon JA, Kingsberg SA, Portman D, et al. (2019). Obstetrics & Gynecology. DOI: 10.1097/AOG.0000000000003514 (opens in a new tab) · PMID 31599847

Design & population
Optional 52-week open-label extension for eligible completers of the RECONNECT trials, with descriptive analyses and no continued placebo arm.
What the study found
Of 684 women entering the extension,272 completed it. Desire and distress improvements were described in the continuing cohort; nausea, flushing and headache remained prominent adverse effects.
Limits on interpretation
Participants were selected from trial completers without serious core-phase adverse events. Attrition and lack of blinding/comparator limit causal interpretation of sustained benefit and safety.

Search & review scope

Targeted web searches of PubMed-indexed primary research and original journal records. Selected abstracts and citation metadata were checked; full-text sections were consulted for the records explicitly labelled full-text. Retrieved records and targeted notice searches were also checked for visible corrections or retractions.. Checked 9 November 2026.

Selected primary research relevant to the named compound, its molecular specification and the endpoints described below.

Narrative selection, not a systematic review, comprehensive safety assessment or complete retraction audit. PubMed/PMC full-text access was intermittent. An abstract or selected-section review cannot replace appraisal of the complete methods, supplements and underlying data. Absence from this selection does not establish absence of research.

Recorded search terms
  • "31599840" bremelanotide
  • site.pubmed.ncbi.nlm.nih.gov PT-141 intranasal double blind 2004 men
  • "Bremelanotide for the Treatment of Hypoactive" "Kingsberg" "2019"
  • site.pubmed.ncbi.nlm.nih.gov bremelanotide long term safety 52 week extension 2019
  • site.pmc.ncbi.nlm.nih.gov/articles/PMC6819021 "satisfying sexual events"

Read the collection’s methods and editorial limits. For formal research, assess and cite the original paper.

Cite this review

HeartPep. PT-141 (bremelanotide): literature review. HeartPep literature library. Reviewed 9 November 2026. https://heartpep.com/uk/research/library/pt-141.

HeartPep is the commercial publisher of this secondary summary. It is not a peer-reviewed primary paper. Cite the original studies for their findings.

Buy from HeartPep.com

Laboratory research only. Not for human or veterinary use.

← All reviews and reference notes